Table 2.
Univariate Analysis of Mortality, PFS, and Acute GvHD
| Variable | Mortality |
PFS |
Grade II-IV Acute GvHD |
||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Donor KIR2DL1 | .0004 | .0013 | .62 | ||||||
| CC | 1 | 1 | 1 | ||||||
| RC | 0.42 | 0.25 to 0.71 | .0013 | 0.48 | 0.28 to 0.82 | .0075 | 1.12 | 0.46 to 2.75 | .8 |
| RR | 0.4 | 0.25 to 0.64 | .0001 | 0.42 | 0.26 to 0.68 | .0003 | 0.89 | 0.38 to 2.06 | .78 |
| Donor KIR haplotype | .92 | .34 | .16 | ||||||
| Cen A/A | 1 | 1 | 1 | ||||||
| Cen A/B | 1.03 | 0.72 to 1.47 | .87 | 1.11 | 0.76 to 1.61 | .59 | 1.28 | 0.75 to 2.2 | .36 |
| Cen B/B | 1.08 | 0.74 to 1.56 | .69 | 1.33 | 0.9 to 1.95 | .15 | 1.68 | 0.98 to 2.88 | .057 |
| Age, years | |||||||||
| < 10 | 1 | 1 | 1 | ||||||
| > 10 | 1.33 | 0.99 to 1.8 | .06 | 1.17 | 0.85 to 1.59 | .33 | 1.5 | 0.97 to 2.31 | .067 |
| Sex | |||||||||
| Female | 1 | 1 | 1 | ||||||
| Male | 0.95 | 0.7 to 1.29 | .74 | 1.04 | 0.76 to 1.43 | .79 | 1 | 0.64 to 1.56 | .99 |
| Race | .054 | .11 | .048 | ||||||
| Black | 1 | 1 | 1 | ||||||
| Other | 0.66 | 0.38 to 1.14 | .14 | 0.61 | 0.34 to 1.08 | .092 | 1.18 | 0.51 to 2.74 | .69 |
| White | 1.14 | 0.77 to 1.69 | .51 | 1.01 | 0.67 to 1.52 | .98 | 1.99 | 1.02 to 3.87 | .044 |
| Primary diseases | .0001 | .0064 | |||||||
| Nonmalignant | 1 | 1 | |||||||
| Hematologic malignancy | 2.32 | 1.4 to 3.84 | .0011 | 1 | 1.4 | 0.75 to 2.61 | .29 | ||
| Solid tumors | 4.26 | 2.26 to 8.01 | .0001 | 1.67 | 1.07 to 2.6 | .024 | 3.27 | 1.46 to 7.31 | .0039 |
| Hematologic malignancies | |||||||||
| ALL | 1 | 1 | 1 | ||||||
| AML | 1.04 | 0.71 to 1.52 | .85 | 1.07 | 0.73 to 1.56 | .72 | 1.17 | 0.66 to 2.06 | .59 |
| Malignant diseases status | .7 | .079 | .39 | ||||||
| CR1 | 1 | 1 | 1 | ||||||
| CR2 | 1.31 | 0.82 to 2.11 | .26 | 1.38 | 0.87 to 2.21 | .17 | 0.64 | 0.3 to 1.41 | .27 |
| CR3/CR4 | 1.09 | 0.51 to 2.35 | .82 | 1.32 | 0.64 to 2.74 | .45 | 0.55 | 0.13 to 2.34 | .42 |
| Refractory/progressive | 1.2 | 0.82 to 1.76 | .35 | 1.67 | 1.13 to 2.46 | .01 | 1.1 | 0.66 to 1.83 | .7 |
| Conditioning type | |||||||||
| Non-TBI | 1 | 1 | 1 | ||||||
| TBI based | 1.06 | 0.78 to 1.43 | .7 | 0.78 | 0.57 to 1.07 | .13 | 0.89 | 0.58 to 1.37 | .59 |
| Conditioning intensity | |||||||||
| Nonmyeloablative | 1 | 1 | 1 | ||||||
| Myeloablative | 0.61 | 0.44 to 0.85 | .0034 | 0.57 | 0.41 to 0.8 | .001 | 0.52 | 0.33 to 0.82 | .0052 |
| Donor type | .19 | .26 | .61 | ||||||
| Haploidentical | 1 | 1 | 1 | ||||||
| Sibling | 0.71 | 0.49 to 1.03 | .069 | 0.75 | 0.51 to 1.1 | .14 | 0.9 | 0.53 to 1.55 | .71 |
| Unrelated | 0.9 | 0.64 to 1.27 | .56 | 0.79 | 0.55 to 1.14 | .21 | 1.19 | 0.72 to 1.95 | .5 |
| T cell depleted | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 1.38 | 1.02 to 1.86 | .034 | 1.29 | 0.95 to 1.76 | .1 | 1.18 | 0.77 to 1.81 | .45 |
| Donor CMV status | .19 | .57 | .23 | ||||||
| Negative | 1 | 1 | 1 | ||||||
| Positive | 1.26 | 0.93 to 1.71 | .13 | 1.17 | 0.85 to 1.6 | .33 | 1.45 | 0.92 to 2.28 | .11 |
| Unknown | 0.72 | 0.29 to 1.78 | .48 | 0.88 | 0.32 to 2.42 | .81 | 1.71 | 0.6 to 4.85 | .31 |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CC, KIR2DL1-C245 homozygous; Cen, centromeric; CMV, cytomegalovirus; GvHD, graft-versus-host disease; HR, hazard ratio; KIR, killer-cell immunoglobulin-like receptors; PFS, progression-free survival; RC, KIR2DL1-R245/C245 heterozygous; RR, KIR2DL1-R245 homozygous; TBI, total-body irradiation.